Increnovo LLC, 730 E Carlisle Ave, Whitefish Bay, WI, 53217, USA.
Radiant Research Services Pvt. Ltd, Bangalore, 560058, India.
Eur J Nutr. 2024 Dec;63(8):3037-3046. doi: 10.1007/s00394-024-03487-8. Epub 2024 Sep 6.
L-Ascorbic acid (vitamin C) is an essential water-soluble vitamin that plays an important role in various physiological functions, including immune health. The stability of vitamin C in the gastrointestinal tract its bioavailability is limited. This study aimed to investigate if a liposomal form of vitamin C can increase absorption compared to standard vitamin C.
In a randomized, double-blind, placebo-controlled, crossover fashion, 19 males and 8 females (n = 27; 36.0 ± 5.1 years, 165.0 ± 6.9 cm, 70.6 ± 7.1 kg) ingested a single-dose of placebo (PLA), 500 mg vitamin C (VIT C), and 500 mg liposomal vitamin C (LV-VIT C, LipoVantage, Specnova, LLC, Tyson Corner, VA, USA). Venous blood samples were collected 0, 0.5-, 1-, 1.5-, 2-, 3-, 4-, 6-, 8-, 12-, and 24-hours after ingestion and were analyzed for plasma and leukocyte vitamin C concentration.
VIT C and LV-VIT C demonstrated significantly greater Cmax and AUC in plasma and in leukocytes compared to placebo (p < 0.001). Additionally, LV-VIT C had significantly higher Cmax (plasma + 27%, leukocytes + 20%, p < 0.001) and AUC (plasma + 21%, leukocytes + 8%, p < 0.001) values as compared to VIT C.
Liposomal formulation of vitamin C increases absorption into plasma and leukocytes.
Clinical Trials Registry - India (CTRI/2023/04/051789).
L-抗坏血酸（维生素 C）是一种必需的水溶性维生素，在包括免疫健康在内的各种生理功能中发挥重要作用。维生素 C 在胃肠道中的稳定性及其生物利用度有限。本研究旨在探讨脂质体形式的维生素 C 是否比标准维生素 C 更能增加吸收。
采用随机、双盲、安慰剂对照、交叉设计，19 名男性和 8 名女性（n=27；36.0±5.1 岁，165.0±6.9cm，70.6±7.1kg）单次摄入安慰剂（PLA）、500mg 维生素 C（VIT C）和 500mg 脂质体维生素 C（LV-VIT C，LipoVantage，Specnova，LLC，Tyson Corner，VA，USA）。摄入后 0、0.5、1、1.5、2、3、4、6、8、12 和 24 小时采集静脉血样，并分析血浆和白细胞维生素 C 浓度。
VIT C 和 LV-VIT C 与安慰剂相比，在血浆和白细胞中均表现出显著更高的 Cmax 和 AUC（p<0.001）。此外，与 VIT C 相比，LV-VIT C 的 Cmax（血浆+27%，白细胞+20%，p<0.001）和 AUC（血浆+21%，白细胞+8%，p<0.001）值也显著更高。
脂质体形式的维生素 C 增加了向血浆和白细胞的吸收。
印度临床试验注册中心（CTRI/2023/04/051789）。
